



December 2021

**Harbour BioMed** **Journal**  
Investor Relations

02142.HK

**HARBOUR**  
BIOMED

# CONTENTS

---

01.Global Roadshow	01
02.Product Update	03
03.HBM as a Thought Leader	04
04.HBM Overview	05
05.Hong Kong Biopharma Industry	07
06.Global Market Overview	08

# 01 Global Roadshow

In November, Harbour BioMed presented at Goldman Sachs Asian Pacific Healthcare Forum 2021, 12<sup>th</sup> Credit Suisse China Investment Conference Changing Gears, and NDRs organized by Morgan Stanley

## Asia Pacific Healthcare Forum 2021



## 12<sup>th</sup> Credit Suisse China Investment Conference



## Morgan Stanley NDR

Morgan Stanley  
HBM POST-RESULTS NDR (VIA ZOOM)

TUESDAY, 02 NOVEMBER 2021 - WEDNESDAY, 10 NOVEMBER 2021

智信会客室  
ZHIXIN MEETING ROOM

智信云路演  
zxroadshow.com

智信会客室  
2021 171期

港股通

**和铂医药 (2142.HK)**

专注于肿瘤及免疫领域创新抗体疗法的生物制药企业

## Attended 20+ NDRs in November

Morgan Stanley



CREDIT SUISSE





# 01 Global Roadshow


## Industrial Securities

Annual Capital Market Summit 2022




## China Securities

Annual Capital Market Summit 2022



## BioCentury

8<sup>th</sup> China Healthcare Summit



### The development of fully-human antibody-drug conjugates (ADC) between Harbour BioMed and Kelun-Biotech are advancing at full speed

With continuous technology breakthroughs, ADC with its unique therapeutic value has gradually become a novel and fast-growing sector. Harbour BioMed leverages its fully-human antibody platforms to collaborate with Kelun-Biotech to develop novel fully-human antibody-drug conjugates targeting two cutting-edge targets in oncology diseases.

**HARBOUR**  
BIOMED



**KELUN-BIOTECH**  
科伦博泰

## 03 HBM as a Thought Leader

### Dr. Hong Que: The Role of Polysorbate in Formulation of Biologics

Dongwu Entrepreneur Pharmacy Forum



**Polysorbate is a common excipient used in the formulation of Biologics.**

**In this lecture, three aspects are introduced:**

- 1) Polysorbate's role in Biologics Formulation
- 2) Polysorbate can undergo a variety of degradation reactions
- 3) Quality control of Polysorbate

## “东吴企业家药学论坛”第五期第54讲

**讲座主题：**聚山梨酯在生物药制剂中的作用与控制策略

**主讲人：**阙红，博士、首席技术官，和铂医药

**时间：**2021年11月30日（周二），18:30-19:30

**地点：**腾讯会议（731-133-607）

**主持人：**许国强，教授、副院长




苏州大学 药学院  
College of Pharmaceutical Sciences, Soochow University

# 04 HBM Overview (02142.HK)


Key Information	
Website – Investor Access	<a href="https://www.harbourbiomed.com/investor">https://www.harbourbiomed.com/investor</a>
Market Cap (11/30, Mil HK\$)	7,026
Total Share Capital (Mil)	768
Circulation Stock (Mil)	768

In November, the Hong Kong stock indexes went down. Compared to first trading day this month, the Hang Seng Index and the Hang Seng Composite Index dropped by 6.7% and 4.7%, respectively. The healthcare sector rebounded slightly. The Hang Seng Healthcare Index rose 0.7%. With a strong stock performance, Harbour BioMed saw a largest one-day increase by 10.6% and surged by 34.8% compared to first trading day this month.

## HBM Stock Performance – November



## The Hang Seng Composite Index (HSCI) – November





## Company News

- 01 The development of fully-human antibody-drug conjugates (ADC) between Harbour BioMed and Kelun-Biotech are advancing at full speed
- 02 HBM Holdings (02142.HK) was up more than 5% approaching market close. The company surged more than 45% accumulatively in the past eight days. A new clinical research of HBM4003 injection was announced for the first time
- 03 Choose the difficult and right thing to do - snowball KOL research on Harbour BioMed
- 04 China's AFC Ajax in innovative therapeutics - Harbour BioMed research
- 05 Harbour BioMed: 3 Unique fully human antibody platforms! Focusing immuno-oncology differentiated therapeutics which are about to enter commercialization
- 06 Harbour BioMed, a pearl of China's innovative medicine
- 07 Snowball KOL research: Harbour BioMed, choose the difficult and right thing to do
- 08 A differentiated drug leader in innovative medicine – Harbour BioMed
- 09 Fully human antibody platforms. It takes several years for a new drug to complete the journey from initial discovery to the marketplace






# 05 Hong Kong Biopharma Industry

## Market Overview

In November, the HSCI closed at 3680.2, down 4.7%. The HSHCI closed at 5386.3, up 0.7%. The China Hong Kong Biotech index (CESHKB.CSI) closed at 12086.2, down 4.5%.

### HK Listing Biopharma Companies (18A)



# 06 Global Market Overview

Global Market Index			
	Closing Price		
	2021.11.01	2021.11.15	2021.11.30
Dow Jones Industrial	35913.8	36087.5	34483.7
Nasdaq Composite	15596.0	15853.9	15537.7
UK FTSE 100	7288.6	7351.9	7059.5
German DAX	15806.3	16148.6	15100.1
France CAC40	6893.3	7128.6	6739.4

HK Market Index			
	Closing Price		
	2021.11.01	2021.11.15	2021.11.30
Hang Seng Index	25154.3	25390.2	23475.3
Hang Seng Composite Index	3860.7	3905.4	3680.2
Hang Seng Tech Index Index	6279.4	6601.2	6028.3
HS China Enterprise	8899.3	9085.6	8368.5
Hang Seng Healthcare Index	5350.0	5537.2	5386.3

Major Global Economic Indicators – August			
Country	Related Indicator	Estimated	Actual
US	Number of Unemployment Benefits Initial Claiming for the week of 11/24 (1k people)	26.0	19.9
US	The Index of Consumer Sentiment of the University of Michigan	72.4	66.8
Eurozone	Sentix Investor Confidence	15.5	18.3
Germany	ZEW Economic Sentiment	20.0	31.7
Germany	Gfk Consumer Confidence	-1.0	-1.6

- The WHO states "the possibility of potential spread of Omicron at the global level is high".
- The European Central Bank executive committee Fabio Panetta said that the Fed's interest rate hike does not mean that the European Central Bank will also raise interest rates. The Vice President Luis de Guindos also said that the European Central Bank will continue to provide support measures.
- The EIA report shows that the US Strategic Petroleum Reserve (SPR) inventories fell to the lowest level since June 2003. The nation's commercial crude oil inventories excluding strategic reserves increased by 1.017 million barrels to 434 million barrels, rose 0.2%.
- The Bank of Korea raised its benchmark interest rates by 25 basis points to 1%, in line with market expectations.

# HARBOUR BIOMED



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE™) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating H2L2, HCAb, HBICE with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

[ir@harbourbiomed.com](mailto:ir@harbourbiomed.com)  
[www.harbourbiomed.com](http://www.harbourbiomed.com)

linkedin:  
<https://www.linkedin.com/company/13244036/admin/>